Some of the Questions KineMed Can Answer:
-
My drug works as I want it to on its target in biochemical assays or in cell culture. Will it retain these desirable features when given to intact animals?
-
My drug works as I want it to in an animal model of disease. Will it show similar benefits when given to patients with the actual disease?
-
My drug shows some of the pharmacologic effects which I am seeking. What is the relationship between dosing regimen and pharmacologic effect? What is the optimal dosing regimen to maximize the benefit and minimize side effects?
-
My drug works in some patients with my intended disease but not others. Are there patient subsets that are more or less likely to respond to my particular drug, and how can I identify them prospectively?
-
The disease I want to treat is slow and variable. Is there a way to determine baseline disease severity in each patient? Can I determine in a short clinical study whether or not my drug will provide long term clinical benefit?
-
I have a candidate biomarker which I want to both validate and use during clinical development. How can I determine if it is “valid” in time to support Phase 3 and product launch?
-
I am working on a speculative target for a chronic disease; all my pre-clinical data are encouraging. Is there a way to probe the validity of my target with a prototype compound in rapid Phase 1b or 2a clinical studies?
Because KineMed can provide significant answers to questions like these across a surprising range of therapy areas, we are ideally suited to address the key challenges of both Translational Medicine and Personalized Medicine. We drive toward selecting the best targets for drug discovery and expeditiously developing the right compounds in the appropriate patients at optimized doses in the clinic to achieve superior medical benefits, both during and after development.
Systematically applying KineMed’s innovations across a portfolio of R&D projects will powerfully reshape the future of the organizations that learn to “ride the wave”.